Discover 5 insights about psoriatic arthritis from rheumatology experts, including pain management strategies, treatment ...

Discover the signs of psoriatic arthritis, from joint pain and skin changes to nail damage and fatigue, plus the latest treatment options for this condition.

Researchers have established that uveitis (a severe inflammatory eye disease) is bidirectionally linked to psoriatic ...

Apremilast treatment in patients with psoriatic arthritis leads to favorable changes in body composition and improves disease ...

Medically reviewed by Stella Bard, MD Psoriatic arthritis (PsA) is a chronic (long-term) condition that includes symptoms of ...

Among patients with PsA, MetS is associated with certain degenerative changes in the spine and entheses but not with peripheral or axial radiographic damage.

Over a 10-year period, METS-IR effectively predicted CV events among patients with PsA, with values greater than 2.48 at baseline conferring the greatest risk.

Biologics targeting interleukin (IL)-12, IL-23, and IL-17 may have valuable safety benefits among older adults with psoriatic disease, as a lower rate of serious infection was observed among these ...

Factors associated with multi-b/tsDMARD failure among patients with PsA included female sex, obesity, depression, axial disease, and increased disease activity.

J&J’s guselkumab gets EU approval for ulcerative colitis, offering new hope for patients who don’t respond to current ...

Johnson & Johnson (J&J) has announced that its dual-acting IL-23 inhibitor Tremfya (guselkumab) has been approved by the European Commission (EC) to treat adults with ulcerative colitis (UC).